May 22 |
Eagle Pharmaceuticals receives delisting notification from Nasdaq
|
May 22 |
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
|
Apr 30 |
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annua...
|
Apr 15 |
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
|
Apr 12 |
Eagle Pharmaceuticals receives notification of deficiency from Nasdaq
|
Apr 12 |
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report onĀ Form 10-K
|
Mar 11 |
Eagle Pharmaceuticals announces resignation of Brian Cahill as CFO
|
Feb 29 |
Eagle Pharmaceuticals to cut 36% of workforce
|
Jan 18 |
Eagle files lawsuit in patent dispute over cancer therapy
|
Jan 18 |
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
|